血滞通胶囊联合阿昔莫司治疗高脂血症的临床研究

目的探讨血滞通胶囊联合阿昔莫司治疗高脂血症的临床疗效。方法选取2015年2月—2016年2月在磁县人民医院进行治疗的高脂血症患者82例,根据治疗方案的差别分为对照组(41例)和治疗组(41例)。对照组口服阿昔莫司胶囊,1粒/次,3次/d。治疗组在对照组的基础上口服血滞通胶囊,1粒/次,3次/d。两组患者均连续治疗12周。比较两组患者治疗前后临床疗效、血脂水平、血清炎性因子水平和内皮功能因子改变。结果治疗后,对照组总有效率为80.49%,显著低于治疗组的95.12%,两组总有效率比较差异具有统计学意义(P0.05)。治疗后,两组总胆固醇(TC)、低密度脂蛋白(LDL-C)和三酰甘油(TG)均显著下降,而高密度脂蛋白(HDL-C)升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组患者上述血脂水平优于对照组(P0.05)。治疗后,两组患者血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平均显著下降(P0.05);且治疗组患者下降比对照组更显著(P0.05)。治疗后,两组患者血清NO显著升高,ET-1水平显著下降,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组NO和ET-1水平优于对照组,两组比较差异有统计学意义(P0.05)。结论血滞通胶囊联合阿昔莫司治疗高脂血症效果显著,可有效降低机体炎性因子水平,改善血管内皮功能因子,具有一定的临床推广应用价值。

Clinical study on Xuezhitong Capsules combined with acipimox in treatment of hyperlipidemia

Objective To explore the clinical efficacy of Xuezhitong Capsules combined with acipimox in treatment of hyperlipidemia. Methods Patients (82 cases) with hyperlipidemia in Cixian People's Hospital from February 2015 to February 2016 were divided into control (41 cases) and treatment (41 cases) groups based on different treatments. Patients in the control group werepoadministered with Acipimox Capsules, 1 grain/time, three times daily. Patients in the treatment group werepoadministered with Xuezhitong Capsules on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy, the change of blood lipid level, serum inflammatory factors and endothelial function in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the control grop was 80.49%, which was significantly lower than 95.12% in the treatment group, and there was difference between two groups (P < 0.05). After treatment, TC, LDL-C, and TG in two groups were significantly decreased, but HDL-C was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the blood lipid level in the treatment group was significantly better than those in the control group (P < 0.05). After treatment, hs-CRP, IL-6, and TNF-α level in two groups was significantly decreased (P < 0.05). And these indexes in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, serum NO level in two groups was significantly increased, ET-1 level was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the improvement of these indicators in the treatment group was better than that in the control group, with significant difference between two groups (P < 0.05).Conclusion Xuezhitong Capsules combined with acipimox has a significant effect in treatment of hyperlipidemia, can reduce the inflammatory factors level and improve endothelial function, which has a certain clinical application value.